Novavax Inc. ($NVAX) Stock Forecast: Up 5.2% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on developing innovative vaccines to address infectious diseases. The company has been actively involved in the development of a COVID-19 vaccine.

Why is Novavax Inc. going up?

NVAX stock is up 5.2% on Jun 11, 2026 19:21

• Despite a series of consecutive declines in recent sessions, Novavax (NVAX) experienced a strong bullish movement today.
• The company's shift to a royalty-based model and concerns regarding limited growth potential had impacted NVAX shares negatively in the past.
• AI-generated trading strategies that emphasized in an analysis may have attracted investors seeking favorable risk-reward scenarios, potentially contributing to the bullish movement.
• There is a possibility that investors are reevaluating the company's profitability and long-term outlook, which could explain the positive market movement for Novavax today.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Inc. stock underperforms Wednesday when compared to competitors

Novavax Inc. (NVAX) shares fell 1.27% to $8.56 on Wednesday, underperforming the broader market as both the NASDAQ Composite and Dow Jones Industrial Average experienced significant declines. The stock closed 28.49% below its 52-week high.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-wednesday-when-compared-to-competitors-0c587347-807949183fbc?mod=mw_quote_news

Novavax set for a seventh straight decline

This article reports that Novavax is anticipated to experience its seventh consecutive daily decline. No further details are provided in the snippet.

https://www.msn.com/en-us/money/topstocks/novavax-rises-after-six-sessions-of-decline/ar-AA25dubD

Novavax (NVAX) Shares Decline Amid Transition to Royalty Model

Novavax (NVAX) shares dropped 2.84% to $8.38, marking a six-session losing streak and an 18% decline since June 1, amidst concerns over its transition to a royalty-based model and limited growth potential. Analysts rate NVAX as a "Hold" with a 2.58 out of 5 score, citing strong profitability but declining COVID-19 vaccine rates. The company's financial strength is poor, with a low GF Score™ of 51/100, indicating significant risks for investors.

https://www.gurufocus.com/news/8908319/novavax-nvax-shares-decline-amid-transition-to-royalty-model

Novavax set for a seventh straight decline

This article states that Novavax is facing a seventh consecutive decline. Due to the brevity of the provided content, further details cannot be extracted, but it indicates a negative trend for the company.

https://www.msn.com/en-us/money/topstocks/novavax-set-for-a-seventh-straight-decline/ar-AA25dubD?ocid=finance-verthp-feeds

(NVAX) Movement as an Input in Quant Signal Sets

This article from Stock Traders Daily discusses Novavax Inc. (NVAX) stock movement, highlighting weak near-term sentiment but strong mid and long-term signals. It provides specific AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, and outlines multi-timeframe signal analysis for various horizons. The report emphasizes the predictive AI's ability to offer exceptional risk-reward setups for traders.

https://news.stocktradersdaily.com/news_release/132/NVAX_Movement_as_an_Input_in_Quant_Signal_Sets_060926044201_1781037721.html

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 6.4% Today

Crude Oil ($CRUDE) Commodity Forecast: Down 6.4% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 7.4% Today

Chainlink ($LINK) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Stellantis NV ($STLA) Stock Forecast: Up 5.0% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Up 5.3% Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Up 5.5% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.1% Today

Novavax Inc. Price History

28.04.2026 - NVAX Stock was down 9.9%

• Despite recent insider selling by Ruxandra Draghia Akli, Novavax Inc. experienced a strong bearish movement today.
• The stock had been performing well in the past few days, outperforming competitors and showing consecutive gains.
• However, the stock closed significantly below its 52-week high, indicating some profit-taking by investors.
• The mixed trading day in the market, along with profit-taking and potential concerns about insider selling, might have contributed to the bearish movement in Novavax's stock price today.

26.04.2026 - NVAX Stock was up 6.3%

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

29.04.2026 - NVAX Stock was up 5.4%

• Despite a favorable market environment yesterday, Novavax Inc. lagged behind its competitors, possibly due to profit-taking following a recent winning streak.
• The sale of 30,000 NVAX shares by an insider initially sparked some market uncertainty, but its overall impact was neutral, indicating a limited influence on the stock's upward trend.
• Novavax's consistent gains and outperformance relative to its peers reflect positive market sentiment and strong trading sessions driving the surge in the stock.
• While not directly linked to stock movement, Novavax's operating margin percentage in financial data may offer insights into the company's financial well-being and future growth prospects. This factor enhances investor confidence and bolsters the bullish momentum.

05.05.2026 - NVAX Stock was down 5.7%

• Novavax Inc. (NVAX) saw a decline in its stock price for the second day in a row, despite overall market gains.
• Investor worries may have been exacerbated by a looming deadline in a legal case accusing the company of making misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline.
• Participation in a healthcare conference did not have a positive impact on Novavax's stock performance.
• The stock's lag behind competitors and its 52-week high have contributed to the prevailing negative investor sentiment towards Novavax Inc., causing a downward trend in the market.

08.05.2026 - NVAX Stock was down 7.4%

• Despite recent positive sentiment, Novavax (NVAX) saw a significant 6.87% drop in its shares, performing below market expectations.
• The decline may be linked to profit-taking following a 10.4% surge post-earnings report, prompting investors to review their holdings.
• While early COVID-19 vaccine trials and analyst enthusiasm initially drove the stock up, market realities and profit concerns likely led to the recent downturn.
• Investors are advised to keep an eye on forthcoming clinical trial outcomes and market conditions for a clearer picture of the stock's future trajectory.

08.05.2026 - NVAX Stock was down 5.3%

• The bearish movement in NVAX's stock price can be attributed to a combination of factors:
• The underperformance compared to competitors and broader market indices on multiple consecutive days indicates a lack of investor confidence in the company's current financial performance and growth prospects.
• The looming deadline for investors to file in a securities class action lawsuit alleging misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline could be adding further downward pressure on the stock.
• Despite bullish sentiments from some traders based on technical analysis and ongoing vaccine trials, the negative news surrounding the lawsuit and consistent stock underperformance seem to be overshadowing any positive momentum.
• Overall, the market sentiment towards NVAX appears cautious and uncertain, with investors closely monitoring both the company's financial results and legal developments.

11.05.2026 - NVAX Stock was up 5.2%

• Despite a series of consecutive declines in recent sessions, Novavax (NVAX) experienced a strong bullish movement today.
• The company's shift to a royalty-based model and concerns regarding limited growth potential had impacted NVAX shares negatively in the past.
• AI-generated trading strategies that emphasized in an analysis may have attracted investors seeking favorable risk-reward scenarios, potentially contributing to the bullish movement.
• There is a possibility that investors are reevaluating the company's profitability and long-term outlook, which could explain the positive market movement for Novavax today.

27.04.2026 - NVAX Stock was up 10.2%

• NVAX stock surged by 13.57% to $10.46, marking the second consecutive day of gains, showcasing strong investor confidence in the company's future prospects.
• The positive market movement could be attributed to the company's promising vaccine development pipeline and potential breakthroughs in the fight against infectious diseases.
• Despite fluctuations in the broader market, NVAX's consistent outperformance indicates a favorable sentiment towards the company's innovative approach and growth potential.
• Investors seem optimistic about NVAX's ability to capitalize on the increasing demand for vaccines, driving the stock price higher amidst a volatile market environment.

20.04.2026 - NVAX Stock was up 5.3%

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

02.05.2026 - NVAX Stock was down 6.2%

• Novavax recently took part in the 2026 Jefferies Global Healthcare Conference to showcase its vaccine technology platform. However, this did not translate into a positive market response for the stock.
• Despite a generally favorable trading day for the broader market, Novavax's stock performed worse than its competitors, closing 4.19% lower.
• AI-driven liquidity mapping analysis for NVAX suggested strong sentiment and potential upside, yet the stock still faced a bearish trend.
• The stock closed below its 52-week high, signaling potential investor concerns about the company's growth prospects or market conditions, contributing to the bearish movement.

02.05.2026 - NVAX Stock was down 5.1%

• NVAX stock experienced a downtrend today, potentially due to the approaching deadline for investors to join a securities class action lawsuit. This lawsuit alleges misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline, resulting in significant financial setbacks.
• Despite participation in a recent conference to discuss its vaccine technology platform, the negative impact of the pending lawsuit appears to have overshadowed any positive developments for the company.
• NVAX stock's underperformance relative to its peers, despite overall positive market conditions, indicates that investor sentiment may be more influenced by legal uncertainties than company-specific news or market trends.
• The stock showed some improvement on a strong trading day, surpassing the broader market. However, it still closed below its 52-week high, suggesting ongoing concerns related to the lawsuit are impacting investor confidence in Novavax's future prospects.

14.04.2026 - NVAX Stock was down 5.0%

• NVAX stock closed at $9.23, showing a bearish movement of 4.05% today.
• Despite recent positive news related to partnerships and earnings, NVAX underperformed its competitors and the broader market.
• The mixed trading session and market sentiment likely played a role in the bearish movement of NVAX stock.
• Investors, especially the "smart money," exhibit caution towards the stock's long-term prospects. Technical indicators lean towards a strong buy, while options data signal a preference for downside protection.